Chondrosarcoma Market

Emerging therapies like INBRX-109, TIBSOVO (ivosidenib), and others are anticipated to drive growth in the Chondrosarcoma market over the coming years.

DelveInsight’s newly released report, “Chondrosarcoma – Market Insights, Epidemiology, and Market Forecast 2034”, provides a comprehensive overview of the disease, covering historical and projected epidemiology along with market dynamics across the United States, EU5 (Germany, Spain, Italy, France, and the UK), and Japan.

Discover about the Chondrosarcoma market report @ https://www.delveinsight.com/report-store/chondrosarcoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Chondrosarcoma Market Report:

• In 2023, the Chondrosarcoma market in the United States was estimated at ~USD 8.5 million, with projections indicating steady growth through 2034. Across the 7MM (US, EU5, and Japan), around 2,300 new cases were reported that year.

• Chondrosarcoma, a rare bone malignancy, is graded I–IV, with the majority of cases classified as Grade II. The US accounted for the highest number of cases among the 7MM, while conventional chondrosarcoma represented nearly 80% of all diagnoses. Within the EU4, France led in market share, whereas Spain had the smallest share.

• Several pharma leaders—Epizyme, Bayer, Eli Lilly, and others—are developing novel treatment approaches to address unmet clinical needs. According to NCCN’s updated guidelines, ivosidenib is recommended for patients with IDH1-mutant conventional or dedifferentiated chondrosarcoma, while ESMO’s 2021 guidelines endorse trabectedin for mesenchymal chondrosarcoma.

• One of the most promising therapies, INBRX-109—a tetravalent DR5 agonist antibody—received both Fast Track and Orphan Drug Designations from the FDA in 2021 for unresectable or metastatic conventional chondrosarcoma. Early clinical studies demonstrated encouraging efficacy, with disease control in 11 of 12 patients and tumor shrinkage in 8 patients. A temporary clinical hold due to liver toxicity was later lifted after protocol modifications.

• Emerging therapies, including INBRX-109, TIBSOVO (ivosidenib), and others, are expected to reshape the treatment landscape. A wide range of companies—such as Aadi Bioscience, Acrotech Biopharma, ADC Therapeutics, Alkermes, Astex, Bayer, BioAtla, Bristol-Myers Squibb, Eli Lilly, Epizyme, Inhibrx, Novartis, Pfizer, PharmaMar, Taiho, and many more—are actively advancing pipeline candidates to improve patient outcomes.

Chondrosarcoma Overview

Chondrosarcoma encompasses a group of cartilage-producing tumors that can range from locally aggressive to highly malignant, showing diverse histological patterns and clinical behavior. They usually arise in bones formed by endochondral ossification and are the most common bone sarcoma in adults over 20. The disease typically affects individuals in their 40s to 60s, with the pelvis being the most frequent site, followed by the femur, humerus, and ribs. Among prognostic factors, histological grade remains the most critical determinant of outcomes.

Chondrosarcoma Market Outlook

Management of chondrosarcoma largely depends on the tumor’s type, grade, and location, with histologic grading (I–III) serving as the most reliable predictor of clinical outcomes. Surgery remains the primary treatment option, as the disease shows limited responsiveness to both radiotherapy and chemotherapy. Surgical interventions—ranging from curettage to radical resection or even amputation—are chosen based on tumor size, anatomical site, and malignancy grade.

Estimating revenue from systemic therapies is challenging, since conventional chondrosarcoma generally resists chemotherapy. This resistance is linked to factors such as slow proliferation rates, P-glycoprotein–mediated drug resistance (notably against doxorubicin), elevated anti-apoptotic proteins like BCL-2, and poor vascularization that restricts drug penetration. The rarity of the disease further complicates the execution of randomized clinical trials. While agents such as cisplatin and doxorubicin (borrowed from osteosarcoma and Ewing sarcoma regimens) are sometimes applied, clinical benefits remain limited. Other drugs, including gemcitabine, ifosfamide, dasatinib, and pazopanib, have also shown only modest effects in aggressive or metastatic cases.

To address these gaps, pharmaceutical companies such as Inhibrx and Servier are advancing novel candidates currently in different stages of clinical development.

Discover how the Chondrosarcoma market is rising in the coming years @ https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Chondrosarcoma Emerging Drugs

• INBRX-109: Inhibrx

• TIBSOVO (ivosidenib): Servier

Scope of the Chondrosarcoma Market Report

• Study Period: 2020-2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Chondrosarcoma Companies: Aadi Bioscience Inc, Acrotech Biopharma LLC, ADC Therapeutics SA, Advenchen Laboratories LLC, Alkermes Plc, Astex Pharmaceuticals Inc, Atlanthera, Bayer AG, BioAtla Inc, BioMed, Valley Discoveries Inc, Bristol-Myers Squibb Co, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Eli Lilly and Co, ENB Therapeutics LLC, Epizyme Inc, Horizon Therapeutics Plc, Incyte Corp, Inhibrx Inc, Iovance Biotherapeutics Inc, Jiangsu Hengrui Medicine Co Ltd, Karyopharm Therapeutics Inc, Les Laboratoires Servier SAS, Merck & Co Inc, Nanode Therapeutics Inc, Nerviano Medical Sciences SRL, NKGen Biotech Inc, Novartis AG, Oncorus Inc, Ono Pharmaceutical Co Ltd, Pfizer Inc, Pharma Mar SA, Rigel Pharmaceuticals Inc, Shanghai Affinity Biomedical Technology Co Ltd, Shanghai De Novo Pharmatech Co Ltd, Taiho Pharmaceutical Co Ltd, and others

• Key Chondrosarcoma Therapies: INBRX-109, TIBSOVO (ivosidenib), and others

• Chondrosarcoma Therapeutic Assessment: Chondrosarcoma current marketed and Chondrosarcoma emerging therapies

• Chondrosarcoma Market Dynamics: Chondrosarcoma market drivers and Chondrosarcoma market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Chondrosarcoma Unmet Needs, KOL’s views, Analyst’s views, Chondrosarcoma Market Access and Reimbursement

To know what’s more in our Chondrosarcoma report, visit https://www.delveinsight.com/report-store/chondrosarcoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Chondrosarcoma Market Report:

1. Chondrosarcoma market report covers a descriptive overview and comprehensive insight of the Chondrosarcoma Epidemiology and Chondrosarcoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

2. The Chondrosarcoma market report provides insights into the current and emerging therapies.

3. The Chondrosarcoma market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Chondrosarcoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chondrosarcoma market.

Got queries? Click here to know more about the Chondrosarcoma market Landscape

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Chondrosarcoma Patient Share (%) Overview at a Glance

5. Chondrosarcoma Market Overview at a Glance

6. Chondrosarcoma Disease Background and Overview

7. Chondrosarcoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Chondrosarcoma

9. Chondrosarcoma Current Treatment and Medical Practices

10. Unmet Needs

11. Chondrosarcoma Emerging Therapies

12. Chondrosarcoma Market Outlook

13. Country-Wise Chondrosarcoma Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Chondrosarcoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Chondrosarcoma Market Outlook 2034

Related Reports:

Chondrosarcoma Pipeline Insights, DelveInsight

“Chondrosarcoma Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chondrosarcoma market. A detailed picture of the Chondrosarcoma pipeline landscape is provided, which includes the disease overview and Chondrosarcoma treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/